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Summary Immunodeprived mice survived a high, otherwise lethal dose of cyclophosphamide (Cy) provided
they had been "primed" with a low dose (50mgkg-1) of the drug 4 days earlier. These combinations were
then tested on 2 oat cell xenograft lines (which are known to reproduce the chemotherapeutic responses of the
parent tumours) grown in immunodeprived mice. In the treatment of the first oat cell xenograft, 200mgkg-I
Cy produced a growth delay of 34 days in the unprimed group and 45 days in the primed group. At a dose of
300mgkg-I a growth delay could not be assessed in the control group as 16/17 of these unprimed mice
bearing this xenograft died. However, 14/22 tumours went into complete remission in this group before death
occurred. In contrast only 3/16 deaths occurred in the group of mice that were primed before receiving the
same challenge dose. In these animals 19/26 tumours went into complete remission and were still completely
absent when the experiment was terminated at 60 days. Using the second oat cell xenograft, 300mgkg- Cy
produced a growth delay of 27 days. However, at this dose level all the animals were dead by day 46. In mice
which had been primed with 50mgkg-I Cy 4 days before the administration of 300mgkg-1 a growth delay
of 32 days was achieved and 2/9 animals were alive at day 60. This study shows that priming allows larger
doses of Cy to be given to immunodeprived mice bearing human tumour xenografts than would normally be
tolerated and that the priming does not alter the anti-tumour efficacy of the large challenge dose as measured
by tumour growth delay or complete remission rate. As the tumours were human in origin it raises the
question whether high dose cyclophosphamide therapy and priming have a role to play in the treatment of
patients with oat cell carcinoma.
It has been known for some time that low dose
cyclophosphamide (Cy) pretreatment or "priming"
4 days before high dose administration improves
mouse survival in otherwise normal C57B1 mice,
(Millar & McElwain, 1978; Millar et al., 1980). It
was also demonstrated that priming does not alter
the efficacy of the large challenge dose in terms of
the curability of the Lewis lung carcinoma or
tumour growth delay of the FS6 fibrosarcoma both
of which are syngeneic in C57B1 mice (Millar
& McElwain, 1978; Millar et al., 1980). The
mechanism underlying these observations is not
understood.
The object of this study was first to establish
whether immunodeprived mice bearing human oat
cell tumour xenografts would withstand high dose
Cy therapy better when they had been primed 4
days earlier with low dose Cy (50mgkg-1), and
then to see if the anti-tumour efficacy of the high
dose was altered by priming.
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Materials and methods
Mice
Female CBA/lac mice were immunosuppressed by
thymectomy at 4 weeks of age, followed 4 weeks
later by 9Gy whole body irradiation, (Steel et al.,
1978).
Tumours
The 2 human oat cell xenograft lines used in these
experiments, HX69 and HX72, (HX being the
acronym for human xenograft), were originally
established from material obtained by surgical
biopsy. The tumours used in these experiments were
in early passage (6-14) and had been shown by
histology and chromosome analysis to have
retained their human characteristics, (Shorthouse et
al., 1980). At the start of each experiment, tumour
fragments measuring about 1-2mm were bilaterally
implanted s.c. into the flanks of these 8-10 week old
mice, as described elsewhere, (Evans et al., 1982).
The animals were used when the tumours had
reached a volume of 0.3-0.5cm3 calculated by the
volume formula V= r LD2/6, where V=volume,
L=longest diameter and D =diameter at right
angles to it. This is the formula for an oblate
spheroid and compensates for the fact that not all
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tumours are spheres. At first measurement (Vo) the
tumours were ranked according to size and
allocated to control or treatment groups to ensure
that each group contained the same spectrum of
tumour sizes.
Cyclophosphamide
Pure cyclophosphamide monohydrate (Koch-Light
Ltd.) was made up in saline and administered by
i.p. bolus injection.
Clearance studies
[14C] ring-labelled cyclophosphamide (kindly
supplied by Dr. Robert Engle, NCI, Bethesda) was
used in this study. Two groups of 3 mice were
treated with 300mgkg-1 Cy spiked with [14C]-
labelled compound. One group had been primed 4
days earlier with 50mgkg-1 Cy. At various times
after the high dose administration, 0.05ml of blood
was taken from the tail. The samples were assayed
for [14C] content as has previously been described
by Wist et al. (1981).
Chemotherapeutic response
The growth rates of individual tumours were
measured by comparing the volume at time t (Vt)
with its volume at the beginning of the experiment
(Vo). The value Vt/Vo was calculated for each
tumour at each sampling time and a mean and s.e.
calculated for each group. Where a death occurred
or a tumour completely regressed, that animal or
tumour was excluded from any further calculation.
Growth delay is defined here as the time taken for
the average tumour volume to recover to the
treatment volume. Where a high percentage of the
mice died or a group of tumours failed to regrow
sufficiently, the results are expressed simply as
deaths or complete remissions.
Statistics
In order to establish the significance of growth
delay differences, individual times taken for
tumours to regrow to treatment volume were
ranked and the non-parameteric Mann-Whitney U-
test used to obtain a P value. Where insufficient
tumours regrew to perform this analysis
satisfactorily, Student's t-test was used to compare
the mean volume ratios at the time of greatest
tumour regression.
Results
Survival studies in non-tumour bearing
immunodeprived mice
From Table I it can be seen that priming improved
the survival of immunodeprived mice at each dose
level of the challenge.
Table I Survival of immunodeprived non-tumour
bearing mice 8 weeks after receiving various doses of
cyclophosphamide (Cy), either alone or after a priming
dose of 50mgkg1 Cy 4 days earlier
Cy
Treatment Survivors
mgkg-1 No prime (%) Prime (%)
300 8/28 (29) 20/28 (71)
350 0/15 (0) 8/15 (53)
400 0/15 (0) 2/15 (13)
Clearance studies
The priming dose did not appear to alter the
pharmocokinetics of the large challange dose as the
clearance of [14C] Cy was the same in both groups,
(Figure 1).
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Figure 1 The clearance of 300mgkg-1 of [14C]-
labelled Cy from the blood of immunodeprived mice.
(0) 300mgkg1 Cy alone; (0) 50mgkg Cy 4 days
before 300mgkg-1 Cy.
Tumour responses
HX69 after 200mgkg-1 Cy It can be seen (Figure
2) that this dose of Cy produced a growth delay of
- 34 days in this tumour line. In the animals that
were primed a growth delay of 45 days was
achieved. In addition there were 3/5 deaths and no
complete remissions in the control group and only
1 death out of 5 and 2/8 complete remissions in the
primed group. At the day of greatest regression, the
volume ratio of the primed group was significantly
smaller than that of the control group (P<0.002).
HX69 after 300mgkg-1 Cy The effect of this dose
of Cy on animal survival is presented in Table II
which shows that 16/17 of the unprimed controls
died. Of the 28 tumours originally present 14 were
in complete remission at the time of death, the
median day of death was 42 and the median day of
complete remission was 26.
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Figure 2 Response of human oat cell carcinoma
xenograft HX69 to 200mgkg-1 Cy. (A) untreated
tumour; (0) 200mgkg-1 Cy alone; (0)
50mgkg-'Cy 4 days before 200mgkg-1; t=death;
CR=complete remission.
Table II Deaths and complete remissions in
immunodeprived mice bearing human oat cell xenograft
HX69 treated with Cy 300mgkg' alone or preceded by a
priming dose Cy 50mgkg1 4 days earlier
Cy Complete
Treatment Deaths remissions
mgkg-1 Mice (%) Tumours (%)
300
No prime 17 16 (94) 28 14 (50)
300
Prime 50 16 3 (19) 26 19 (73)
In the primed animals only 3/16 died and 19/26
tumours went into complete remission. The median
day of death was again 42 and the median day of
complete remission was 26.
HX72 after 300mgkg-' cyclophosphamide The
oat cell xenograft HX72 had a tendency to cause
deaths in untreated animals (unpublished
observation). For example, in this experiment 1/4
untreated tumour bearing mice died by Day 21.
Figure 3 shows that all the animals in the
unprimed group were dead by Day 46. In the
primed group there were 2 survivors out of 9 at 60
days. The growth delay in both groups were
similar, being -32 days for the primed group and
27 days for the controls.
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Figure 3 Response of human oat cell carcinoma
xenografts HX72 to 300mgkg-1 Cy. (0) 300mgkg-'
alone; (0) 50mgkg-1 Cy 4 days before
300mgkg-1 Cy. Other symbols as in Figure 2.
HX72 after 200mgkg- cyclophosphamide To en-
sure that the slightly increased growth delays seen
in the primed animals were not due to the fact that
they received slightly greater total doses of Cy in
this experiment a stat dose of 250mgkg- was
given to the controls and compared with the
response in the group that received 50mgkg-1
prime 4 days before 200mgkg-1. To bias the
experiment against ourselves the stat dose was
given to the controls at the time of the prime, the
challenge dose in the primed group being given 4
days later, (Figure 4). Here, the growth delay of the
primed group appeared to be slightly shorter than
that of the control group when both are measured
from the day of challenge (23 vs. 30 days), but the
growth delays were not significantly different when
they were measured from Day 3, i.e. when
treatment began, (27 vs. 30 days).
Discussion
The first part of this study dealt with the ability of
a small dose of Cy to prime against a large dose of
the drug in immunodeprived mice. The survival
data show that Cy pretreatment confers the same
type of protection against the toxic effects of high
dose Cy in immunodeprived mice as it does in
normal mice (Millar & McElwain 1978). This is
perhaps unexpected as in the course of
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Figure 4 Response of human oat cell carcinoma
xenograft HX72 to 250mgkg- Cy administered in
various ways. (0) 50mgkg-1 Cy on Day 2 and
200mgkg-1 on Day 6; (A) 250mgkg1 Cy on Day 2.
Other symbols as in Figure 2.
immunodeprivation the mice received 9Gy total
body irradiation (TBI) which would have been
lethal to the mice but for a priming dose of
cytosine arabinoside (200mgkg-1) given 2 days
before the TBI (Millar et al., 1978a; Steel et al.,
1978). These animals were primed twice therefore,
first with cytosine arabionoside before irradiation
and then about 4 weeks later with low dose Cy
before high dose Cy and in both instances the
normal tissue-damaging effect of the the challange
dose was reduced. This demonstrates that mice are
capable of being primed twice with different drugs
against widely different cytotoxic agents. This
finding may have some bearing on clinical research
where normal tissue damage limits the multi-modal
therapy under investigation.
It must be stressed in the case of Cy that
although the Cy prime reduced the normal tissue
toxicity of the challenge dose it did not completely
abolish toxic deaths, particularly in situations where
the tumour itself caused fatalities or weakened the
animals (Figure 3). Also, although cell synchrony
may play a part in the priming of cytosine
arabinoside on irradiation (Millar et al., 1982), the
mechanism by which Cy primes on itself remains
unclear. The simplest explanation, namely that the
priming dose alters the pharmacokinetics of the
challenge drug, is unlikely for 2 reasons. First,
direct measurement of the clearance of labelled Cy
was unaltered by priming and second, the anti-
tumour efficacy of the challenge dose of drug was
not impaired by priming. If priming caused the
challenge dose to be more rapidly metabolised, thus
reducing normal tissue damage, this would have
been reflected in less effective tumour control.
However, there was no evidence of this.
Indeed, within any one xenograft line (and in
every experiment to larger or lesser degree) priming
reduced normal tissue toxicity whilst maintaining
anti-tumour efficacy. In other words the therapeutic
gain seen in putatively immunocompetent tumour-
bearing mice (Millar & McElwain 1978, Millar et
al., 1978b; 1980) was produced in human xenograft
bearing animals too. It is possible, bearing in mind
the correlation between the xenograft
chemosensitivity and parent tumour (Shorthouse et
al., 1980), that some oat cell tumours in patients
may also be sensitive to high dose Cy. If Cy
priming similarly reduces normal tissue toxicity in
man then it may be possible to administer larger
doses than would normally be tolerated, to patients
with oat cell carcinoma, or more conventional
doses with greater safety and improved therapeutic
index.
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